<?xml version='1.0' encoding='utf-8'?>
<document id="26116278"><sentence text="Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for atorvastatin and its metabolites."><entity charOffset="93-105" id="DDI-PubMed.26116278.s1.e0" text="atorvastatin" /></sentence><sentence text="Atorvastatin is the most commonly used of all statins to lower cholesterol"><entity charOffset="0-12" id="DDI-PubMed.26116278.s2.e0" text="Atorvastatin" /><entity charOffset="63-74" id="DDI-PubMed.26116278.s2.e1" text="cholesterol" /><pair ddi="false" e1="DDI-PubMed.26116278.s2.e0" e2="DDI-PubMed.26116278.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26116278.s2.e0" e2="DDI-PubMed.26116278.s2.e1" /></sentence><sentence text=" Atorvastatin is extensively metabolized in both gut and liver to produce several active metabolites"><entity charOffset="1-13" id="DDI-PubMed.26116278.s3.e0" text="Atorvastatin" /></sentence><sentence text=" The purpose of the present study is to develop a physiologically based pharmacokinetic (PBPK) model for atorvastatin and its two primary metabolites, 2-hydroxy-atorvastatin acid and atorvastatin lactone, using in vitro and in vivo data"><entity charOffset="105-117" id="DDI-PubMed.26116278.s4.e0" text="atorvastatin" /><entity charOffset="151-178" id="DDI-PubMed.26116278.s4.e1" text="2-hydroxy-atorvastatin acid" /><entity charOffset="183-203" id="DDI-PubMed.26116278.s4.e2" text="atorvastatin lactone" /><pair ddi="false" e1="DDI-PubMed.26116278.s4.e0" e2="DDI-PubMed.26116278.s4.e0" /><pair ddi="false" e1="DDI-PubMed.26116278.s4.e0" e2="DDI-PubMed.26116278.s4.e1" /><pair ddi="false" e1="DDI-PubMed.26116278.s4.e0" e2="DDI-PubMed.26116278.s4.e2" /><pair ddi="false" e1="DDI-PubMed.26116278.s4.e1" e2="DDI-PubMed.26116278.s4.e1" /><pair ddi="false" e1="DDI-PubMed.26116278.s4.e1" e2="DDI-PubMed.26116278.s4.e2" /></sentence><sentence text=" The model was used to predict the pharmacokinetic profiles and drug-drug interaction (DDI) effect for atorvastatin and its metabolites in different DDI scenarios"><entity charOffset="103-115" id="DDI-PubMed.26116278.s5.e0" text="atorvastatin" /></sentence><sentence text=" The predictive performance of the model was assessed by comparing predicted results to observed data after coadministration of atorvastatin with different medications such as itraconazole, clarithromycin, cimetidine, rifampin and phenytoin"><entity charOffset="128-140" id="DDI-PubMed.26116278.s6.e0" text="atorvastatin" /><entity charOffset="176-188" id="DDI-PubMed.26116278.s6.e1" text="itraconazole" /><entity charOffset="190-204" id="DDI-PubMed.26116278.s6.e2" text="clarithromycin" /><entity charOffset="206-216" id="DDI-PubMed.26116278.s6.e3" text="cimetidine" /><entity charOffset="218-226" id="DDI-PubMed.26116278.s6.e4" text="rifampin" /><entity charOffset="231-240" id="DDI-PubMed.26116278.s6.e5" text="phenytoin" /><pair ddi="false" e1="DDI-PubMed.26116278.s6.e0" e2="DDI-PubMed.26116278.s6.e0" /><pair ddi="false" e1="DDI-PubMed.26116278.s6.e0" e2="DDI-PubMed.26116278.s6.e1" /><pair ddi="false" e1="DDI-PubMed.26116278.s6.e0" e2="DDI-PubMed.26116278.s6.e2" /><pair ddi="false" e1="DDI-PubMed.26116278.s6.e0" e2="DDI-PubMed.26116278.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26116278.s6.e0" e2="DDI-PubMed.26116278.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26116278.s6.e0" e2="DDI-PubMed.26116278.s6.e5" /><pair ddi="false" e1="DDI-PubMed.26116278.s6.e1" e2="DDI-PubMed.26116278.s6.e1" /><pair ddi="false" e1="DDI-PubMed.26116278.s6.e1" e2="DDI-PubMed.26116278.s6.e2" /><pair ddi="false" e1="DDI-PubMed.26116278.s6.e1" e2="DDI-PubMed.26116278.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26116278.s6.e1" e2="DDI-PubMed.26116278.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26116278.s6.e1" e2="DDI-PubMed.26116278.s6.e5" /><pair ddi="false" e1="DDI-PubMed.26116278.s6.e2" e2="DDI-PubMed.26116278.s6.e2" /><pair ddi="false" e1="DDI-PubMed.26116278.s6.e2" e2="DDI-PubMed.26116278.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26116278.s6.e2" e2="DDI-PubMed.26116278.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26116278.s6.e2" e2="DDI-PubMed.26116278.s6.e5" /><pair ddi="false" e1="DDI-PubMed.26116278.s6.e3" e2="DDI-PubMed.26116278.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26116278.s6.e3" e2="DDI-PubMed.26116278.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26116278.s6.e3" e2="DDI-PubMed.26116278.s6.e5" /><pair ddi="false" e1="DDI-PubMed.26116278.s6.e4" e2="DDI-PubMed.26116278.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26116278.s6.e4" e2="DDI-PubMed.26116278.s6.e5" /></sentence><sentence text=" This population based PBPK model was able to describe the concentration-time profiles of atorvastatin and its two metabolites reasonably well in the absence or presence of those drugs at different dose regimens"><entity charOffset="90-102" id="DDI-PubMed.26116278.s7.e0" text="atorvastatin" /></sentence><sentence text=" The predicted maximum concentration (Cmax), area under the concentration-time curve (AUC) values and between-phase ratios were in good agreement with clinically observed data" /><sentence text=" The model has also revealed the importance of different metabolic pathways on the disposition of atorvastatin metabolites"><entity charOffset="98-110" id="DDI-PubMed.26116278.s9.e0" text="atorvastatin" /></sentence><sentence text=" This PBPK model can be utilized to assess the safety and efficacy of atorvastatin in the clinic"><entity charOffset="70-82" id="DDI-PubMed.26116278.s10.e0" text="atorvastatin" /></sentence><sentence text=" This study demonstrated the feasibility of applying PBPK approach to predict the DDI potential of drugs undergoing complex metabolism" /><sentence text=" " /></document>